Inclusion Criteria:

- Age >= 18 years

- Clear clinical and radiographic evidence of primary high grade glioma (HGG) as judged
by the Mayo multidisciplinary neuro-oncology team (World Health Organization [WHO]
grade III-IV, including glioblastoma) regardless of IDH and MGMT status

- Planned neurosurgical resection of tumor

- Judged to not be at risk of significant clinical risk (i.e. herniation) with
radiation-induced edema prior to resection

- No prior history of cranial radiotherapy

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2

- Negative pregnancy test done =< 14 days prior to registration, for women of
childbearing potential only

- Ability to complete questionnaire(s) by themselves or with assistance

- Provide written informed consent

- Planning to receive adjuvant radiotherapy at enrolling institution

- Willing to provide tissue and/or blood samples for correlative research purposes

- Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (obtained =< 14 days prior to
registration)

- Platelet count >= 80,000/mm^3 (80 x 10^9/L) (obtained =< 14 days prior to
registration)

- Hemoglobin (Hgb) >= 9 g/dL (=< 14 days prior to registration)

Exclusion Criteria:

- Any of the following:

- Pregnant women

- Nursing women

- Men or women of childbearing potential who are unwilling to employ adequate
contraception

- Unwillingness to participate in study

- Investigator discretion that enrollment on the study would pose undo harm or risk to
the patient

- Non-MRI compatible implanted medical device

- Use of systemic anti-cancer therapy within the previous 3 months

- Medical contraindication to craniotomy and tumor resection

- Pathologic confirmation of grade I-II glioma, brain metastasis, or other brain tumor

- Note: Patients with a history of grade I-II glioma are eligible if they have only
received surgery as treatment and now there is concern for transformation to
grade III-IV tumor

- Primary spinal cord glioma or primary brainstem glioma

- Residual tumor of excessive volume or eloquent location per investigator discretion

- Patients who are unwilling or unable to comply with study procedures

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 3/20/2024. Questions regarding updates should be directed to the study team contact.